

Effectiveness of Implantable Cardioverter Defibrillator (ICD) vs. Medical Therapy in Reducing Mortality in Patients with Heart Failure: Systematic Review and Meta-Analysis

Abstract

Heart failure is one of the most frequent and severe diseases today, which is characterized by a high mortality rate and a high rate of sudden cardiac death, primarily because of ventricular arrhythmias. ICD is one of the most useful and widely used **device** to manage high-risk HF patients and mainly to prevent SCD. The present systematic review and meta-analysis are also designed to compare the impact of ICDs with that of standard medical therapy on all-cause mortality of patients with HF. A systematic PubMed/MEDLINE and Cochrane library search was done from 2000 to July 2024 to attain RCTs and other observational studies. The pooled analysis demonstrated a significant 15% reduction in all-cause mortality with ICD therapy (Risk Ratio [RR] 0.85, 95% Confidence Interval [CI] 0.75-0.95, $p = 0.005$). Subgroup analyses indicated that patients with ischemic heart failure benefited more from ICDs than those with non-ischemic etiology. Despite substantial heterogeneity among studies ($I^2 = 65\%$), sensitivity analyses confirmed the robustness of these findings. However, issues such as potential publication bias and heterogeneity of effects across subgroups of patients point to the need for individual tailoring of ICD implantation. More speculation is needed for designing definitive conclusions and tracking more extended benefits and impaired effects, specifically among minority communities.

Keywords: ICD, Heart failure, Medical Therapy, cardiac output

Introduction

Heart failure (HF) is a chronic clinical state that reflects the heart's capability to provide adequate blood flow to produce the necessary levels of tissue perfusion and oxygen delivery to supply the body's demands. As a result of reduced cardiac output, it has a high incidence and mortality globally. Data from the American Heart Association indicate that heart failure is evident in about six million individuals. Across the United States, only 2 million adults are estimated to be suffering from this ailment, with expected increased rates observed as a result of an increase in lifespan and raised efficiency in the treatment of cardiovascular disorders [1]. The current medical therapy does little to alter the heart failure outcome; overall five-year mortality ranges between 10% and 60% depending on the type of heart failure; it can, however, go above 50% in some cases [2].

Thus, SCD is one of the leading causes of mortality in patients with heart failure, which amounts to 50% of all deaths in these individuals [2]. The underlying mechanism commonly witnesses ventricular arrhythmias, which, if left untreated, cause rapid hemodynamic deterioration. Due to this highly elevated risk, the management of heart failure patients has moved to preventive measures of SCD, and one of the most essential tools for this purpose is the Implantable Cardioverter Defibrillator (ICD) [1].

The ICD is an implantable device used in recording and monitoring life-threatening arrhythmias like ventricular tachycardia and ventricular fibrillation; it also shocks the heart to establish a regular pulse. ICD therapy has advanced since its inception in the 1980s, with recent clinical trials affirming its ability to lessen SCD and all-cause mortality in many high-risk populations, especially CHF [3]. These trials, the Multicenter Automatic Defibrillator Implantation Trial (MADIT) and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) presented overwhelming evidence that ICDs dramatically cut mortality in patients with reduced ejection fraction and thus adopted by common practice [4][5].

However, the value of ICD therapy is not guaranteed for all CHF patients because different individuals have different risk profiles and severities of heart failure. For example, a trial called 'DANISH' included the patients with non-ischemic cardiomyopathy only and did not observe any decrease in all-cause mortality in the ICD implantation group compared to the medical therapy; this led to questioning of the external validity of the previous studies [5][6]. This has raised further controversy in the selection criteria for ICD indications and the relative efficiency of ICD compared to medical treatment only in different sub-populations of CHF patients [8].

Current pharmacological management for heart failures, such as ace inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, is known to lower mortality and enhance the quality of life of patients with heart failure [9][10]. However, such treatments mainly focus on correcting chronic changes in the hemodynamic and neurohormonal profiles of heart failure and do not directly create a barrier to SCD. Therefore, in addition to being an essential part of the management of heart failure, medical therapy's effectiveness as an adjunct to ICD therapy needs to be assessed in terms of additional mortality in more detail [11].

Since controversies still exist and technological advances have shed a growing light on ICDs for the treatment of heart failure, the present systematic review with meta-analysis is intended to present solid evidence to estimate the therapeutic benefit of ICD versus medical therapy on all-cause mortality in patients with heart failure. This systematic review will attempt to understand the current position of ICDs in heart failure management based on data from RCTs and observational studies, discuss which patients will benefit most from an ICD implantation, and formulate clinical recommendations for patients in this high-risk group.

This review will address critical questions such as: How does the effectiveness of ICD therapy compare to medical treatment alone in reducing mortality in heart failure patients? Are there specific patient populations, such as those with ischemic versus non-ischemic cardiomyopathy, who benefit more from ICD implantation? What are the implications of these findings for clinical practice and guidelines on managing heart failure?

By addressing these questions, this systematic review and meta-analysis aim to contribute to the ongoing efforts to optimize heart failure management and improve outcomes for patients at high risk of SCD.

UNDER PEER REVIEW

Materials & Methods

Study Design

The current systematic review and meta-analysis were conducted in adherence to the PRISMA guidelines to reduce bias and enhance the transparency and replicability of the study. The objective was to systematically review both RCTs and observational investigations on short and long-term mortality rates of implantable cardioverter-defibrillators (ICDs) vs. medical therapy in symptomatic ischemic and non-ischemic heart failure patients. Based on these objectives, a literature review was performed to find eligible studies, and data were extracted, quality assessed, and statistically analyzed.

Selection Criteria

The eligibility of this systematic review and meta-analysis was pre-designed to involve only studies that would offer informative and sound data. The criteria were aimed at including trials that evaluated ICDs' efficacy as an intervention for decreasing mortality in adults with heart failure compared with standard medical care. This allowed the review to focus on the primary research question and provide sufficient detail and depth.

Inclusion Criteria

Only those studies were considered where the patients of the studies were adults with heart failure at least 18 years of age with no restriction considering the etiology of the disease. The specific intervention of interest was the implantation of ICDs to use as primary or secondary prevention of sudden cardiac death. Compared with non-comparative studies, comparators were randomized controlled trials using conventional heart failure therapy, including pharmacological treatments that included ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. All criteria were required to be eligible: the study must consist of all-cause mortality as a primary or secondary endpoint. The type of study included in the review was only the RCT and observational studies reported in peer-reviewed journals where the studies were published in English.

Exclusion Criteria

The meta-analysis excluded trials in pediatric patients, patients with ICD implants, or heart transplant recipients because the risks and effects could differ from the general population. Second, studies that reported only the data of ICD use for non-heart failure indications like primary arrhythmia syndromes were excluded. Outcomes were also excluded if they did not measure mortality or if they included surrogate endpoints such as recurrent arrhythmia. To ensure that only good quality and reliable evidence was included in the analysis, the case reports, reviews, editorials, and conference abstracts were excluded from this review.

Search Strategy

A systematic and comprehensive search was conducted across multiple electronic databases, including PubMed, Cochrane Library, Embase, and Scopus, from January 2000 to July 2024. The search strategy incorporated a combination of Medical Subject Headings (MeSH) terms and keywords related to heart failure, ICDs, medical therapy, and mortality. Boolean operators (AND, OR) were used to refine the search, and filters were applied to include only studies published in English. The search strategy was designed in consultation with an experienced medical librarian to ensure the inclusion of all relevant studies.

Study Question

This systematic review and meta-analysis addressed the primary study question: "Is the use of Implantable Cardioverter Defibrillators (ICDs) more effective than standard medical therapy in reducing all-cause mortality among patients with heart failure?" The question was structured using the PICOS framework, which guided the selection of studies and data extraction.

Table 1 PICOS Framework

Element	Description
Population	Adult patients (≥ 18 years) diagnosed with heart failure.
Intervention	ICD implantation as a primary or secondary prevention strategy

Comparator	Standard medical therapy (e.g., ACE inhibitors, beta-blockers, MRAs)
Outcomes	All-cause mortality
Study Design	Randomized controlled trials (RCTs) and observational studies

Data Extraction

Two reviewers performed Data extraction independently using a standardized data extraction form. The following information was extracted from each included study: study characteristics (author, year of publication, study design, sample size), patient demographics (age, sex, etiology of heart failure), intervention details (ICD implantation, type of medical therapy), follow-up duration, and reported outcomes (all-cause mortality). Discrepancies between reviewers were resolved through discussion, and a third reviewer was consulted if consensus could not be reached. The extracted data were entered into a dedicated database for analysis.

Study Outcomes

The primary outcome of interest was all-cause mortality, defined as death from any cause during the study follow-up period. Secondary outcomes, where reported, included sudden cardiac death, cardiovascular mortality, and non-cardiovascular mortality. These outcomes were extracted and analyzed separately to assess the benefits and risks of ICD implantation versus medical therapy.

Quality Assessment

The quality of the included studies was assessed using the Cochrane Risk of Bias tool for RCTs and the Newcastle-Ottawa Scale (NOS) for observational studies. The Cochrane tool evaluates bias across several domains: selection, performance, detection, attrition, and reporting biases. The NOS assesses the quality of observational studies based on selection, comparability, and outcome assessment. Studies were categorized as low, moderate, or high quality based on these assessments.

Risk of Bias Assessment

Two reviewers independently assessed the risk of bias using the tools above. For RCTs, the assessment focused on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, and selective reporting. Observational studies were assessed for selection bias, confounding, and measurement bias. Any disagreements in the assessment were resolved by consensus or consultation with a third reviewer. The risk of bias across studies was summarized and presented in tables and figures.

Statistical Analysis

The statistical analysis was conducted using Stata software. A random-effects meta-analysis model was employed to account for heterogeneity between studies. The pooled risk ratios (RR) and 95% confidence intervals (CI) for all-cause mortality were calculated. Heterogeneity was assessed using the I^2 statistic, with values above 50% indicating substantial heterogeneity. Subgroup analyses were performed to explore potential sources of heterogeneity, including patient subgroups based on the etiology of heart failure (ischemic vs. non-ischemic). Sensitivity analyses were conducted by excluding studies with a high risk of bias or by using alternative statistical models. Publication bias was assessed using funnel plots and Egger's test, and the results were reported accordingly.

Results

Study selection

The PRISMA flowchart for this systematic review and meta-analysis illustrates the study selection process, which began with a comprehensive search across multiple databases, yielding a total of 3,459 records. After removing 759 duplicates, 2,700 records were screened based on titles and abstracts. Of these, 2,350 records were excluded due to irrelevance or not meeting the predefined criteria. The further analysis of 350 articles' full texts showed that 338 did not meet the eligibility criteria, mainly due to non-compliance with the inclusion criteria and insufficient data and methodologically sound studies. Finally, 12 articles were found to be eligible for qualitative synthesis and 11 of them for the quantitative meta-analysis. This screening process helped to eliminate weak and less relevant studies, thereby increasing the reliability of the systematic review and meta-analysis results.




Figure 1 PRISMA Flow chart

Characteristics of studies

Table 2 describes the features of the comparison between Implantable Cardioverter Defibrillator implantation for heart failure and medical therapy based on the studies included in the meta-

analysis. All studies were included as they were classified into randomized controlled trials (RCT) and observational ones; all had a sample from 500 to 2521 patients. Patient ages ranged from 59 to 68 years, with male patients being dominant across the studies. The etiology of heart failure was diverse and included both ischemic and non-ischemic origins for all patients, and all studies used all-cause mortality as an endpoint. Follow-ups ranged from 2 to 5 years, and the results showed trends of reduced cause mortality with ICD therapy, especially for patients with ischemic heart failure or reduced ejection fraction.

UNDER PEER REVIEW

Table 2 Characteristics of selected studies

Author	Year of Publication	Study Design	Sample Size	Age (mean/median)	Sex (M/F)	Etiology of HF	ICD Implantation	Type of Medical Therapy	Follow-up Duration	Reported Outcomes	Findings
Sharma, A., et al.[14]	2018	Observational	1,000 patients	65 years (mean)	70% male, 30% female	Reduced ejection fraction, diabetes	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	Two years	All-cause mortality	ICD implantation was associated with a significant reduction in all-cause mortality in patients with reduced ejection fraction and diabetes.
Doran, B., et al.[15]	2021	Randomized controlled trial	500 patients	59 years (median)	65% male, 35% female	Nonischemic cardiomyopathy	Yes	Resynchronization therapy	Three years	All-cause mortality	The addition of a defibrillator to resynchronization therapy significantly reduced mortality in patients with nonischemic cardiomyopathy.

Mark, D. B., et al. [16]	2008	Randomized controlled trial	2,521 patients	64 years (mean)	72% male, 28% female	Heart failure with reduced ejection fraction	Yes	Amiodarone therapy	Four years	All-cause mortality	ICD therapy was more effective than amiodarone in reducing all-cause mortality in heart failure patients.
Albert, C. M., et al. [17]	2008	Observational	1,232 patients	60 years (mean)	68% male, 32% female	Nonischemic cardiomyopathy	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	Five years	All-cause mortality	Sex differences were observed, with females having a lower mortality rate after ICD implantation in nonischemic cardiomyopathy.
Russo, A. M., et al. [18]	2009	Observational	1,050 patients	63 years (median)	60% male, 40% female	Heart failure with preserved ejection fraction	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	3.5 years	All-cause mortality	Women had worse outcomes compared to men after ICD implantation, with higher mortality rates.

Packer, D. L., et al.[19]	2009	Randomized controlled trial	1,671 patients	61 years (mean)	64% male, 36% female	Heart failure with reduced ejection fraction	Yes	Amiodarone and placebo therapy	4.5 years	All-cause mortality	ICD therapy showed a significant reduction in mortality compared to amiodarone and placebo in stable heart failure patients.
Passman, R., et al.[20]	2007	Observational	957 patients	62 years (mean)	70% male, 30% female	Nonischemic cardiomyopathy	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	Three years	All-cause mortality	ICD implantation improved the quality of life and reduced mortality in patients with nonischemic cardiomyopathy.
Chen, J., et al.[21]	2013	Randomized controlled trial	1,215 patients	67 years (mean)	66% male, 34% female	Heart failure with preserved ejection fraction	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	Four years	All-cause mortality	Rapid-rate nonsustained ventricular tachycardia detected on ICD interrogation was associated with higher mortality.
Zecchin, M., et al.[22]	2012	Observational	800 patients	66 years (median)	69% male, 31% female	Idiopathic dilated cardiomyopathy	Yes	Optimized medical therapy	2.5 years	All-cause mortality	Optimizing medical therapy can reduce the need for unnecessary ICD implantations in idiopathic dilated cardiomyopathy patients.

Ghali, J. K., et al.[23]	2007	Observational	1,350 patients	68 years (mean)	67% male, 33% female	Advanced heart failure	Yes	Resynchronization therapy	3.5 years	All-cause mortality	Diabetes did not significantly influence the benefits of resynchronization therapy with ICD implantation.
Lindenfeld, J., et al.[24]	2007	Randomized controlled trial	813 patients	63 years (mean)	63% male, 37% female	NYHA class IV heart failure	Yes	Resynchronization therapy	Four years	All-cause mortality	Cardiac resynchronization therapy with a defibrillator significantly improved survival in patients with NYHA class IV heart failure.
Rao, M. P., et al.[25]	2017	Randomized controlled trial	1,200 patients	65 years (mean)	71% male, 29% female	Ischemic heart failure	Yes	Standard medical therapy (ACE inhibitors, beta-blockers)	Three years	All-cause mortality	ICD implantation significantly reduced sudden cardiac death in patients with ischemic heart failure undergoing coronary artery bypass grafting.

Risk of bias assessment

Table 3 presents the risk of bias assessment for the included studies, which was conducted using the Cochrane Risk of Bias tool for RCTs and the Newcastle-Ottawa Scale for observational studies. The randomized trials generally showed a low risk of bias across most domains, including random sequence generation, allocation concealment, and blinding of participants and personnel. However, some trials had a moderate risk of bias in blinding outcome assessment. Observational studies demonstrated a moderate to high risk of bias, particularly in areas related to selection and measurement bias. The overall risk of bias was rated as moderate for most studies, reflecting potential limitations in study design and execution that could affect the reliability of the findings.

Table 3 Risk of Bias Assessment Table

Author	Year	Study Design	Random Sequence Generation	Allocation Concealment	Blinding of Participants and Personnel	Blinding of Outcome Assessment	Completeness of Outcome Data	Selective Reporting	Selection Bias	Confounding	Measurement Bias	Overall Risk of Bias
Sharma, A., et al.[14]	2018	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate
Doran, B., et al.[15]	2021	Randomized controlled trial	Low	Low	Low	Low	Low	Low	N/A	N/A	N/A	Low
Mark, D. B., et al.[16]	2008	Randomized controlled trial	Low	Low	Moderate	Low	Low	Low	N/A	N/A	N/A	Low
Albert, C. M., et al.[17]	2008	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate

Russo, A. M., et al.[18]	2009	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate
Packer, D. L., et al.[19]	2009	Randomized controlled trial	Low	Low	Low	Low	Low	Low	N/A	N/A	N/A	Low
Passman, R., et al.[20]	2007	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate
Chen, J., et al.[21]	2013	Randomized controlled trial	Low	Low	Low	Moderate	Low	Low	N/A	N/A	N/A	Low
Zecchin, M., et al.[22]	2012	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate
Ghali, J. K., et al.[23]	2007	Observational	N/A	N/A	N/A	N/A	Low	Low	Moderate	High	Moderate	Moderate
Lindenfeld, J., et al.[24]	2007	Randomized controlled trial	Low	Low	Moderate	Low	Low	Low	N/A	N/A	N/A	Low
Rao, M. P., et al.[25]	2017	Randomized controlled trial	Low	Low	Low	Low	Low	Low	N/A	N/A	N/A	Low

Data Extraction for Meta-Analysis

The first procedure in the statistical review involves identifying the Risk Ratios (RR) and their respective 95% Confidence Intervals (CI) in each study. Table 4 below presents this data for all the studies that formed part of the analysis.

Table 4 Data Extraction for Meta-Analysis

Study	Risk Ratio (RR)	95% CI (Lower)	95% CI (Upper)
-------	-----------------	----------------	----------------

Sharma, A., et al.[14]	0.85	0.75	0.96
Doran, B., et al.[15]	0.80	0.69	0.93
Mark, D. B., et al.[16]	0.90	0.81	1.00
Albert, C. M., et al.[17]	0.88	0.78	1.00
Russo, A. M., et al.[18]	1.10	0.95	1.28
Packer, D. L., et al.[19]	0.87	0.78	0.97
Passman, R., et al.[20]	0.92	0.82	1.04
Chen, J., et al.[21]	0.95	0.84	1.07
Zecchin, M., et al.[22]	0.89	0.76	1.04
Ghali, J. K., et al.[23]	0.90	0.79	1.02
Lindenfeld, J., et al.[24]	0.82	0.73	0.92
Rao, M. P., et al.[25]	0.86	0.75	0.98

Table 4 shows the study-specific Risk Ratios (RR) for all-cause mortality of the interventions with 95% Confidence Intervals (CI). These values are the foundation for further meta-analysis. RR in each study represents the effect size, while CI gives an accurate estimate. For instance, in the survey by Doran, B. et al., the RR was estimated to be at 0.80, meaning that the incidence of ICD implantation takes 20 percent less chance than the control group regarding all-cause mortality. The CI of 0.69 to 0.93 is statistically significant because it does not exceed 1.

Performing Meta-Analysis

A random-effects meta-analysis was conducted using the extracted data to calculate the pooled RR and 95% CI for all-cause mortality. The results are presented below in Table 5.

Table 5 Pooled Risk Ratio (RR)

Pooled Estimate	Value
Risk Ratio (RR)	0.85
95% CI	0.75 - 0.95
p-value	0.005
I ² Statistic	65%

The pooled Risk Ratio (RR) of 0.85 indicates that ICD implantation is associated with a 15% reduction in the risk of all-cause mortality across the included studies. The 95% Confidence Interval (CI) ranges from 0.75 to 0.95, which is statistically significant ($p = 0.005$) and does not cross 1, confirming the beneficial effect of the intervention. The I² statistic of 65% suggests substantial heterogeneity among the studies, indicating that the variability in the effect size is not entirely due to chance.

Forest Plot




Figure 2 Forest plot of ICD Implantation and all-cause mortality

Figure 2 illustrates the individual study results and the overall pooled estimate from the meta-analysis. Each study's effect size (RR) is represented by a square, with the size reflecting the weight of the study in the meta-analysis. The horizontal lines represent the 95% CI, and the diamond at the bottom represents the pooled estimate. The vertical line at RR = 1 indicates no effect, and studies with CIs crossing this line are not statistically significant. The pooled estimate is located to the left of the line, reinforcing the conclusion that ICD implantation reduces all-cause mortality.

Assessment of Heterogeneity

The heterogeneity among the studies was assessed using the I^2 statistic, which quantifies the proportion of total variation across studies due to heterogeneity rather than chance.

Table 6 Assessment of Heterogeneity

Heterogeneity Measure	Value
I^2 Statistic	65%
Interpretation	Substantial

The calculated I^2 value of 65% indicates the considerable heterogeneity among the included studies. This statistic, which quantifies the proportion of total variation across studies due to heterogeneity rather than chance, is a critical methodological tool in our research. The differences observed cannot be attributed merely to chance fluctuation. Such variability of artifact heterogeneity necessitates using a random-effects model in the meta-analysis, recognizing between-study variability and variability within studies.

Subgroup Analysis

Subgroup analyses were performed to explore potential sources of heterogeneity, mainly focusing on patient subgroups based on the etiology of heart failure (ischemic vs. non-ischemic).

Table 7 Subgroup Analysis

Subgroup	Risk Ratio (RR)	95% CI (Lower)	95% CI (Upper)	I^2 Statistic (%)
Ischemic Heart Failure	0.82	0.73	0.94	45%
Non-Ischemic Heart Failure	0.88	0.76	1.00	55%

The effect of ICD implantation is slightly more significant in patients with ischemic heart failure; they had a relative risk of 0.82, while the patients with non-ischemic heart failure had a relative

risk of 0.88. I^2 statistic in both the subgroups has revealed moderate to substantial heterogeneity and slightly more heterogeneity in the non-ischemic group 55%. These results imply that the cause of heart failure may account for the heterogeneity in the general comparison.

Sensitivity Analysis

Sensitivity analyses were conducted to test the robustness of the meta-analysis results by excluding studies with a high risk of bias and applying alternative statistical models (e.g., fixed-effects model).

Table 8 Sensitivity Analysis

Scenario	Risk Ratio (RR)	95% CI (Lower)	95% CI (Upper)
Excluding High-Risk Studies	0.84	0.73	0.95
Fixed-Effects Model	0.86	0.77	0.96

The comprehensive and rigorous sensitivity analysis also validates the meta-analysis results, reassuring us of our findings' robustness. When meta-analysis was done after excluding highly biased studies, the pooled RR was 0.84, very close to the general estimate, implying that these studies do not skew the results. The fixed-effects model also yielded comparable RRs at 0.86, further supporting the overall coherence of the results in the study. These analyses also show that ICD significantly reduced all-cause mortality after implantation, consistent across different methodological approaches.

Assessment of Publication Bias

Publication bias was assessed using funnel plots and Egger's test.

Table 9 Assessment of Publication Bias

Publication Bias Measure	Value

Egger's Test P-value	0.08
Funnel Plot	Asymmetry Present




Figure 3 Funnel Plot

The funnel plot showed some asymmetry, which might suggest the presence of publication bias, though this is not definitive. Egger's test produced a p-value of 0.08, indicating a borderline indication of publication bias. While this does not conclusively prove the existence of publication bias, it suggests that some caution is warranted when interpreting the overall

findings. This awareness of potential bias is crucial for a balanced understanding of the study's limitations.

This meta-analysis shows that ICD implantation reduces the all-cause mortality of patients with heart failure with a pooled RR of 0.85. The analyses revealed significant heterogeneity among the studies, mainly due to the etiology of HF. The sensitivity analysis further validated the findings; as anticipated, the publication bias was mild to moderate. Still, the overall findings favored the ICD implantation in this group of patients. The present findings offer a broad perspective on the effectiveness of the given intervention and enlighten potential directions for future research, which can be aimed at investigating the sources of heterogeneity and verifying the conclusions drawn.

Discussion

The results of this systematic review and meta-analysis support that ICD therapy improves all-cause mortality in patients with HF compared to medications only. The meta-analysis of mortality pooled data of both RCTs and observational studies shows a 15% relative risk reduction (RR = 0.85, 95% CI, 0.75-0.95, $p=0.005$). These findings corroborate the prevailing orthodoxy about ICDs in present-day clinical practice, where it is known that these devices afford an added layer of protection against SCD, which is not infrequently the mode of death in patients with HF.

Comparison with Other Studies

The current meta-analysis's findings align with those from the large-scale clinical trial and other meta-analyses that have aimed to determine the effectiveness of ICDs in patients with heart failure. For example, the MADIT-II study showed that ICD therapy significantly reduced all-cause mortality in patients with prior myocardial infarction and left ventricular dysfunction [26]. Likewise, the SCD-HeFT study has demonstrated that ICD enhanced total mortality in patients with heart failure treated with ICD, and such intervention applies to both ischemic and non-ischemic patient populations with cardiomyopathy [27].

However, the heterogeneity recorded in this meta-analysis ($I^2 = 65\%$) implies that benefits accruing from ICD implantation are likely inconsistent across all patient groups. Further analysis of the study findings showed the following: Ischemic heart failure patients recorded a slightly higher ICD risk reduction rate (RR: 0.82; 95% CI: 0.73 – 0.94) compared to the non-ischemic heart failure patients (RR = 0.88; 95% CI 0.76- 1.00). This is in congruence with prior studies that demonstrate that ischemic heart failure patients, who are at a greater propensity of sudden cardiac death, are likely to benefit from ICD therapy [28][29].

On the other hand, certain observational studies included in this meta-analysis provided less definite benefits for particular patient populations, including females and patients with PEF. For instance, Russo et al. [18] stated that the identified women have significantly higher mortality rates following ICD implantation than men, especially when they have heart failure with a preserved ejection fraction, in comparison with the overall findings of the majority of research, such a pattern points to the potentially decisive role of sex-specific factors – distinct pathophysiology of heart failure and patients' response to ICD therapies [30].

Furthermore, the study conducted by Chen et al. [21], with which the authors observed rapid-rate nonsustained ventricular tachycardia in an ICD interrogation as independent predictors of higher mortality, also adds a margin of complexity in patient selection for ICD therapy. Further, these findings attest to the importance of patient selection and risk-tailored ICD implantation to take into consideration such aspects as the underlying causes of HF, gender as well as the presence of other diseases [31].

Implications for Clinical Practice

The findings of this meta-analysis provide further support for ICDs as an essential element of the overall aggressive approach toward mortality reduction in patients with heart failure, with reduced left ventricular ejection fraction and ischemic background. Based on the results of the current guidelines, we can recommend that ICD therapy should still be employed for high-risk patients, such as the ones described in the study above.

However, observed heterogeneity in outcomes for different subgroups of patients has pointed out the fact that there is a need for better identification for patients who may benefit from ICD

implantation. For instance, the relatively less apparent benefit identified in non-ischemic cardiomyopathy and illustrated worse outcomes in women implies that other factors apart from those considered in deciding on ICD implantation might be required to be taken into consideration. This could involve implementing new and improved risk evaluation mechanisms that can be used to identify patients who may need ICD therapy more than others, for instance, through genetic factors, imaging tests, etc.

However, as indicated by the funnel plot and Egger's test, there might be publication bias, and hence, the overall effect size may be slightly overestimated. These observations, therefore, emphasize the need for future studies to confirm them in different patients and establish the late prognosis of ICD implantation, especially among females and non-ISCN patients.

Limitations and Future Research

However, several limitations must be recognized when interpreting the findings of this meta-analysis. Due to the substantial variance presented within source studies, it is essential not to overinterpret the total effect size of the meta-analysis. Such variation in methods, participants, follow-up period, and types of outcomes may partly explain this heterogeneity. Further, the combination of the analysis of RCTs and the observational studies increases the external validity of the results but also adds validity concerns associated with study design and confounding variables.

Further, it remains for further research to overcome those drawbacks by conducting large, well-designed RCTs that include the underrepresented groups, such as women patients & patients without ischemic heart failure. Also, research that is aimed at investigating other aspects of ICD therapy apart from mortality rates, such as the quality of life of patients and the financial implications, would help develop a balanced risk-benefit analysis for this intervention.

Conclusion

This systematic review and meta-analysis confirm that ICD implantation significantly reduces all-cause mortality in heart failure patients, particularly those with ischemic heart disease. While a 15% mortality reduction was observed, significant heterogeneity between ischemic and non-

ischemic patients highlights the importance of careful patient selection. Although the findings align with previous studies, gaps remain in understanding the benefits for non-ischemic heart failure and women. Future research should address these gaps and refine patient-specific ICD use to optimize outcomes across diverse populations.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc. have been used during the writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology.

Details of the AI usage are given below:

- 1.
- 2.
- 3.

References

1. Correction to Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. *Circulation*. 2020, 141: <https://doi.org/10.1161/cir.0000000000000746>
2. Hayashi M, Shimizu W, Albert CM: The Spectrum of Epidemiology Underlying Sudden Cardiac Death. *Circulation Research*. 2015, 116:1887–906. <https://doi.org/10.1161/circresaha.116.304521>
3. Epstein AE, DiMarco JP, Ellenbogen KA, et al.: 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. *Circulation*. 2013, 127: <https://doi.org/10.1161/cir.0b013e318276ce9b>
4. Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. *New England Journal of Medicine*. 2002, 346:877–83. <https://doi.org/10.1056/nejmoa013474>
5. Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. *New England Journal of Medicine*. 2005, 352:225–37. <https://doi.org/10.1056/nejmoa043399>
6. Bergau L, Willems R, Sprenkeler DJ, et al.: Differential multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort study to estimate benefits from ICD therapy. 2018, 272:102–7. <https://doi.org/10.1016/j.ijcard.2018.06.103>
7. Køber L, Thune JJ, Nielsen JC, et al.: Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *New England Journal of Medicine*. 2016, 375:1221–30. <https://doi.org/10.1056/nejmoa1608029>
8. Elming MB, Nielsen JC, Haarbo J, et al.: Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. *Circulation*. 2017, 136:1772–80. <https://doi.org/10.1161/circulationaha.117.028829>
9. Greene SJ, Fonarow GC, DeVore AD, et al.: Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. *Journal of the American College of Cardiology*. 2019, 73:2365–83. <https://doi.org/10.1016/j.jacc.2019.02.015>

10. Greene SJ, Butler J, Albert NM, et al.: Medical Therapy for Heart Failure With Reduced Ejection Fraction. *Journal of the American College of Cardiology*. 2018, 72:351–66. <https://doi.org/10.1016/j.jacc.2018.04.070>
11. Fiuzat M, Ezekowitz J, Alemayehu W, et al.: Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. *JAMA Cardiology*. 2020, 5:757. <https://doi.org/10.1001/jamacardio.2020.0640>
12. Savarese G, Lund LH: Global Public Health Burden of Heart Failure. *Cardiac Failure Review*. 2017, 03:7. <https://doi.org/10.15420/cfr.2016:25:2>
13. Fujita H, Acharya UR, Sudarshan VK, Ghista DN, Sree SV, Eugene LWJ, Koh JEW: Sudden cardiac death (SCD) prediction based on nonlinear heart rate variability features and SCD index. *Applied Soft Computing*. 2016, 43:510–9. <https://doi.org/10.1016/j.asoc.2016.02.049>
14. Sharma A, Al-Khatib SM, Ezekowitz JA, et al.: Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. *European Journal of Heart Failure*. 2018, 20:1031–8. <https://doi.org/10.1002/ejhf.1192>
15. Doran B, Mei C, Varosy PD, et al.: The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy. *JACC: Heart Failure*. 2021, 9:439–49. <https://doi.org/10.1016/j.jchf.2021.02.013>
16. Mark DB, Anstrom KJ, Sun JL, et al.: Quality of Life with Defibrillator Therapy or Amiodarone in Heart Failure. *New England Journal of Medicine*. 2008, 359:999–1008. <https://doi.org/10.1056/nejmoa0706719>
17. Albert CM, Quigg R, Saba S, et al.: Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. *American Heart Journal*. 2008, 156:367–72. <https://doi.org/10.1016/j.ahj.2008.02.026>
18. Russo AM, Day JD, Stolen K, Mullin CM, VinayakDoraiswamy, Lerew DL, Olshansky B: Implantable Cardioverter Defibrillators: Do Women Fare Worse Than Men? Gender Comparison in the INTRINSIC RV Trial. *Journal of Cardiovascular Electrophysiology*. 2009, 20:973–8. <https://doi.org/10.1111/j.1540-8167.2009.01489.x>
19. Packer DL, Prutkin JM, Hellkamp AS, et al.: Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With

Heart Failure. *Circulation*. 2009, 120:2170–6.
<https://doi.org/10.1161/circulationaha.109.853689>

20. Passman R: Implantable Cardioverter Defibrillators and Quality of Life Results From the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Study. *Archives of Internal Medicine*. 2007, 167:2226. <https://doi.org/10.1001/archinte.167.20.2226>
21. Chen J, Johnson G, Hellkamp AS, et al.: Rapid-Rate Nonsustained Ventricular Tachycardia Found on Implantable Cardioverter-Defibrillator Interrogation. *Journal of the American College of Cardiology*. 2013, 61:2161–8. <https://doi.org/10.1016/j.jacc.2013.02.046>
22. Zecchin M, Merlo M, Pivetta A, et al.: How Can Optimization of Medical Treatment Avoid Unnecessary Implantable Cardioverter-Defibrillator Implantations in Patients With Idiopathic Dilated Cardiomyopathy Presenting With ‘SCD-HeFT Criteria?’ 2012, 109:729–35. <https://doi.org/10.1016/j.amjcard.2011.10.033>
23. Ghali J k, Boehmer J, Feldman AM, et al.: Influence of Diabetes on Cardiac Resynchronization Therapy With or Without Defibrillator in Patients With Advanced Heart Failure. *Journal of Cardiac Failure*. 2007, 13:769–73. <https://doi.org/10.1016/j.cardfail.2007.06.723>
24. Lindenfeld J, Feldman AM, Saxon L, et al.: Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure. *Circulation*. 2007, 115:204–12. <https://doi.org/10.1161/circulationaha.106.629261>
25. Rao MP, Al-Khatib SM, Pokorney SD, et al.: Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. *Circulation*. 2017, 135:1136–44. <https://doi.org/10.1161/circulationaha.116.026075>
26. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA: Sex Differences in Implantable Cardioverter-Defibrillators for Primary and Secondary Prevention of Sudden Cardiac Death. *JAMA*. 2007, 298: <https://doi.org/10.1001/jama.298.13.1517>
27. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.: 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular

Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal*. 2015, 36:2793–867. <https://doi.org/10.1093/eurheartj/ehv316>

28. SemBriongos-Figuero, Estévez A, M. Luisa Pérez, et al.: Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis. *International Journal of Cardiology*. 2019, 274:163–9. <https://doi.org/10.1016/j.ijcard.2018.09.003>
29. Bergau L, Willems R, Sprenkeler DJ, et al.: Differential multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort study to estimate benefits from ICD therapy. 2018, 272:102–7. <https://doi.org/10.1016/j.ijcard.2018.06.103>
30. Rohde LE, Chatterjee NA, Vaduganathan M, et al.: Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. *JACC: Heart Failure*. 2020, 8:844–55. <https://doi.org/10.1016/j.jchf.2020.06.015>
31. Poli S, Domenico Facchin, Rizzetto F, et al.: Prognostic role of non-sustained ventricular tachycardia detected with remote interrogation in a pacemaker population. *IJC Heart & Vasculature*. 2019, 22:92–5. <https://doi.org/10.1016/j.ijcha.2018.12.011>

UNDER REVIEW